Poor
Mostly Aligned
Patient Risk:
Low
Summary
Only a subset of claims align with the label. A few statements are supported (desloratadine as active metabolite of loratadine; loratadine converted to desloratadine; desloratadine 5 mg daily dosing; desloratadine half-life ~27 hours), while several assertions are contradicted (first-pass metabolism bypass; onset times; hepatic impairment avoidance) and numerous claims are not present in the supplied label sections (absent). Overall alignment is limited.
Category Scores
Accurate Statements
Desloratadine is the active metabolite of loratadine.
12.3
Loratadine is converted into desloratadine in the body to produce its effects.
12.3
Desloratadine dose is 5 mg daily.
12.3
Desloratadine half-life is 27 hours.
12.3
Unsupported Statements
Desloratadine can be taken if loratadine didn't relieve allergies.
Not supported by the provided label sections; no guidance on sequential switching in the label excerpts.
Desloratadine bypasses first-pass metabolism in the liver.
Contradicted by label; desloratadine is described as a major metabolite of loratadine with hepatic metabolism detailed in 12.3.
Taking desloratadine directly skips that conversion step.
Not supported by the provided label sections.
Skipping that conversion step can lead to faster or stronger relief for some people when loratadine alone falls short.
Not supported by the provided label sections.
Desloratadine often works better for non-responders to loratadine.
Not supported by the provided label sections.
Desloratadine provides similar symptom control for allergic rhinitis and urticaria.
Not supported by the provided label sections.
Desloratadine provides slightly superior symptom control for allergic rhinitis and urticaria.
Not supported by the provided label sections.
Desloratadine has comparable safety profiles to loratadine.
Not supported by the provided label sections.
Both loratadine and desloratadine are second-generation antihistamines.
Not supported by the provided label sections.
Both loratadine and desloratadine don't typically cause drowsiness.
Not supported by the provided label sections.
Loratadine onset is 1-3 hours.
Not supported by the provided label sections.
Loratadine half-life is 8-14 hours.
Not supported by the provided label sections.
Desloratadine onset is 1 hour.
Contradicted by label; onset times described in 12.3 differ.
Loratadine dose is 10 mg daily.
Not supported by the provided label sections.
Loratadine has a response rate of about 70% effective.
Not supported by the provided label sections.
Desloratadine has up to 80% response rate in trials.
Not supported by the provided label sections.
Desloratadine is better for partial responders.
Not supported by the label sections.
Wait at least 24 hours after your last loratadine dose before starting desloratadine.
Not supported by the provided label sections.
There are no significant interactions between loratadine and desloratadine.
Not supported by the provided label sections.
Doubling up raises antihistamine levels unnecessarily.
Not supported by the provided label sections.
Standard switch: stop loratadine, begin desloratadine the next day.
Not supported by the provided label sections.
Desloratadine and loratadine share rare side effects such as headache.
Not supported by the provided label sections.
Desloratadine and loratadine share rare side effects such as fatigue.
Not supported by the provided label sections.
Desloratadine and loratadine share rare side effects such as dry mouth.
Not supported by the provided label sections.
Desloratadine has no added risks beyond loratadine.
Not supported by the provided label sections.
Pregnant individuals should consult a doctor.
Not supported by the provided label sections.
Breastfeeding individuals should consult a doctor.
Not supported by the provided label sections.
If taking erythromycin or other metabolism-affecting drugs, consult a doctor.
Not supported by the provided label sections.
No sedation issues for driving.
Not supported by the provided label sections.
If neither loratadine nor desloratadine works, allergies might need nasal steroids (e.g., fluticasone).
Not supported by the provided label sections.
If neither loratadine nor desloratadine works, allergies might need montelukast.
Not supported by the provided label sections.
If neither loratadine nor desloratadine works, allergies might need immunotherapy.
Not supported by the provided label sections.
Fexofenadine (Allegra) is an alternative.
Not supported by the provided label sections.
Fexofenadine is less affected by food.
Not supported by the provided label sections.
Fexofenadine is good for skin allergies.
Not supported by the provided label sections.
Cetirizine (Zyrtec) is an alternative.
Not supported by the provided label sections.
Cetirizine has faster onset but more sedating.
Not supported by the provided label sections.
Levocetirizine is cetirizine's active form.
Not supported by the provided label sections.
Over-the-counter combinations with pseudoephedrine add decongestant power.
Not supported by the provided label sections.
Contradictions
Low
AI Statement
Desloratadine bypasses first-pass metabolism in the liver.
Label Reference
12.3
Low
AI Statement
Desloratadine onset is 1 hour.
Label Reference
12.3
Low
AI Statement
Desloratadine should be avoided in people with severe liver impairment.
Label Reference
8.7
Important Omissions
No explicit contraindications section present in the extracted label; safety data on hepatic impairment exist but are not summarized in the omissions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label contains standard safety data for desloratadine with no high-risk, unaddressed safety concerns evident from the provided claims; several assertions are unsubstantiated or contradicted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Claims are largely not supported or are misaligned with the label; a subset is supported (active metabolite, conversion, desloratadine dosing and PK). Significant extraneous or incorrect inferences (first-pass metabolism, sequential switching, comparative efficacy) are present.
Suggested Improvement
Restrict claims to those explicitly supported by label sections (12.3 for PK/metabolism; 2.5, 8.7 for dosing and hepatic impairment; 8.1–8.8 for pregnancy, lactation, and safety). Avoid statements about switching from loratadine, comparative efficacy, or non-label drug combinations unless explicitly supported by the label.